WHAT S IN BETWEEN DOSE AND RESPONSE?
|
|
- Rodger Chambers
- 6 years ago
- Views:
Transcription
1 WHAT S IN BETWEEN DOSE AND RESPONSE? Pharmacokinetics, Pharmacodynamics, and Statistics Marie Davidian Department of Statistics North Carolina State University Outline 1 Introduction 2 What is pharmacokinetics? 3 What is pharmacodynamics? 4 Population PK/PD and statistics the history 5 An example 6 PK/PD today 7 Concluding remarks Warning: There are very few equations in this talk! davidian Greenberg Lecture I: PK, PD, and Statistics 1 Greenberg Lecture I: PK, PD, and Statistics 2 1 Introduction 1 Introduction What do we want in a drug? Safety Efficacy Can people take it, and does it work? The usual paradigm: Look at what goes in and what comes out, often by asking If we were to administer this drug at some dose to a population of interest, what would the mean response be? And how does it compare to that for other drugs or other doses of this drug? Key message, part I: Understanding what goes on between dose (administration) and response can yield insight on How best to choose doses at which to evaluate a drug How best to use a drug in a population How best to use a drug to treat individual patients or subpopulations of patients And a lot more Key concepts: Pharmacokinetics (PK) what the body does to the drug Pharmacodynamics (PD) what the drug does to the body Greenberg Lecture I: PK, PD, and Statistics 3 Greenberg Lecture I: PK, PD, and Statistics 4 1 Introduction 1 Introduction dose PK concentration PD response Key message, part II: Understanding what goes on between dose (administration) and response for both individuals and the population Relies critically on combining physiological (mathematical) modeling with STATISTICAL MODELING Population PK/PD Statistical modeling is a integral part of the science Key message, part III: Combining mathematical and statistical modeling is becoming more generally recognized as a critical tool in the study of treatment of disease Greenberg Lecture I: PK, PD, and Statistics 5 Greenberg Lecture I: PK, PD, and Statistics 6
2 2 What is Pharmacokinetics? 2 What is Pharmacokinetics? What the body does to the drug Goals of drug therapy: From a pharmacologist s point of view, for an individual patient or type of patient Achieve therapeutic objective (cure disease, mitigate symptoms,etc) Minimize toxicity Minimize difficulty of administration Optimize dose regimen to address these issues Implementation of drug therapy: To achieve this, must determine How much? How often? To whom? Different for different patients? ages? genders? Under what conditions (or not)? Information on this: Pharmacokinetics Study of how the drug moves through the body and the processes that govern this movement Greenberg Lecture I: PK, PD, and Statistics 7 Greenberg Lecture I: PK, PD, and Statistics 8 2 What is Pharmacokinetics? 2 What is Pharmacokinetics? What goes on inside: ADME Routes of drug administration: Intravenously, Intramuscularly, Subcutaneously, Orally, Basic assumptions and principles: There is a site of action where drug will have its effect Magnitudes of response, toxicity are functions of drug concentration at the site of action Drug cannot be placed directly at site of action, must move there Concentrations at site of action are determined by how drug is absorbed, distributed to tissues/organs, metabolized, excreted (eliminated) (how it moves over time) Concentrations must be kept high enough to produce response, low enough to avoid toxicity = Therapeutic window Cannot measure concentration at site of action directly, but can measure in blood/plasma/serum; reflect those at site Greenberg Lecture I: PK, PD, and Statistics 9 Greenberg Lecture I: PK, PD, and Statistics 10 2 What is Pharmacokinetics? 2 What is Pharmacokinetics? Result: ADME dictates concentration at site of action, but can not be observed directly Plasma concentrations have information about ADME = monitor concentration over time Understanding ADME allows manipulation of concentrations Data for 4 subjects given same oral dose of anti-asthmatic theophylline: Theophylline conc (mg/l) Subject Subject Subject 10 Subject 12 Theophylline conc (mg/l) Time (hr) Time (hr) Greenberg Lecture I: PK, PD, and Statistics 11 Greenberg Lecture I: PK, PD, and Statistics 12
3 2 What is Pharmacokinetics? 2 What is Pharmacokinetics? Absorption Elimination Absorption Elimination Concentration (mg/l) Concentration (mg/l) Duration of Effect Therapeutic Window Time (hr) Time (hr) Greenberg Lecture I: PK, PD, and Statistics 13 Greenberg Lecture I: PK, PD, and Statistics 14 2 What is Pharmacokinetics? 2 What is Pharmacokinetics? Multiple dosing: Ordinarily, sustaining doses are given to replace drug eliminated, maintain concentrations in therapeutic window over time Steady state : amount lost = amount gained Principle of superposition: Frequency, amount for multiple-dose regimen governed by: ADME Width of therapeutic window Greenberg Lecture I: PK, PD, and Statistics 15 Greenberg Lecture I: PK, PD, and Statistics 16 2 What is Pharmacokinetics? 2 What is Pharmacokinetics? Effect of different frequency: Same dose and ADME characteristics Effect of different elimination characteristics: Same dose and frequency Greenberg Lecture I: PK, PD, and Statistics 17 Greenberg Lecture I: PK, PD, and Statistics 18
4 2 What is Pharmacokinetics? 2 What is Pharmacokinetics? Need a way to deduce ADME from plasma concentrations One-compartment model with first-order absorption, elimination: Compartmental modeling: Represent the body by a system of compartments depending on ADME processes Can be grossly simplistic, but often sufficient approximation Compartments may or may not have physical meaning oral dose D X(t) k a k e dx(t) dt dx a(t) dt = k ax a(t) k ex(t), X(0) = 0 = k ax a(t), X a(0) = F D F = bioavailability, X a(t) = amount at absorption site C(t) = X(t) = kadf {exp( ket) exp( kat)}, ke = Cl/V V V (k a k e) V = volume of compartment, Cl = clearance Greenberg Lecture I: PK, PD, and Statistics 19 Greenberg Lecture I: PK, PD, and Statistics 20 2 What is Pharmacokinetics? 2 What is Pharmacokinetics? Two-compartment model, IV bolus injection: Dose D (instantaneous) D : dx(t) dt dx tis(t) dt X(t) ke k 12 k21 Greenberg Lecture I: PK, PD, and Statistics 21 X tis(t) = k 21X tis(t) k 12X(t) k ex(t), X(0) = D = k 12X(t) k 21X tis(t), X tis(0) = 0 C(t) = A 1 exp( λ 1t) + A 2 exp( λ 2t) Extensions: More compartments (eg peripheral tissues), nonlinear kinetics (saturation at high concentrations) Physiologically-Based Pharmacokinetic (PBPK) models Result: Deterministic model for time-concentration within a subject Based on (albeit simplified) physiological considerations Depends on PK parameters characterizing ADME processes for that subject Multiple doses : Apply superposition principle, eg C(t) = { } D d Cl V exp (t td) V d:td<t Greenberg Lecture I: PK, PD, and Statistics 22 2 What is Pharmacokinetics? 3 What is Pharmacodynamics? Only half the battle! What is a good concentration? What is the therapeutic window? Is it the same for everyone? Further complicating matters: Recall theophylline Identical dose = substantial variation in drug concentrations among people due to substantial variation in ADME among people = each subject may have same model but with different PK parameters Idea: What the drug does to the body Characterizing dose-response relationship in the population is not informative enough One reason: inter-subject variation in PK Ie, Inter-subject variation in concentrations for same dose = inter-subject variation in response for same dose Understanding concentration-response for individuals provides more precise information for deciding how to dose Pharmacodynamics: Relationship of response (drug effect) to drug concentration Greenberg Lecture I: PK, PD, and Statistics 23 Greenberg Lecture I: PK, PD, and Statistics 24
5 3 What is Pharmacodynamics? 3 What is Pharmacodynamics? Furthermore: Inter-subject variation in concentration due to different PK is only part of the reason subjects vary in their responses Response varies across subjects who achieve the same concentrations = Study concentration-response within subjects and how it varies across subjects Understanding inter-subject variation in concentrations and responses gives insight on width and placement of therapeutic window and how it varies across subjects PD models: Model concentration-response within a given subject Empirical rather than physiological in basis Eg the so-called E max model for continuous response Emax E0 R = E EC, C = concentration 50/C Each subject has his/her own PD parameters Ideally : Concentration at site of action Realistically : Concentration in plasma Complications: Choice of R, measurement error in C Time lag : difference between concentration in blood and at site Greenberg Lecture I: PK, PD, and Statistics 25 Greenberg Lecture I: PK, PD, and Statistics 26 3 What is Pharmacodynamics? 3 What is Pharmacodynamics? Pharmacokinetics: Learn about PK parameters in a suitable compartment model For individual subjects and how they vary in the population In order to understand how to dose individual subjects and develop guidelines for dosing certain types of subjects (eg elderly) To achieve desired concentrations Pharmacodynamics: Completing the story Learn about concentrations eliciting desired responses and inter-subject variation in how this happens In order to gain understanding of the width and variation (among subjects) of the therapeutic window And use this knowledge to refine dosing strategies Ultimate objectives: dose Improve drug development process Inform better drug use in routine clinical care PK variation concentration PD variation response Greenberg Lecture I: PK, PD, and Statistics 27 Greenberg Lecture I: PK, PD, and Statistics 28 4 Population PK/PD and Statistics 4 Population PK/PD and Statistics The story begins: In the early 1970s with Lewis B Sheiner, MD Greenberg Lecture I: PK, PD, and Statistics 29 Greenberg Lecture I: PK, PD, and Statistics 30
6 4 Population PK/PD and Statistics 4 Population PK/PD and Statistics Traditional PK studies: Often in Phase I, II Get basic information, eg, average concentrations achieved, insight into toxicities Healthy volunteers, different from patient population, homogeneous Small number of subjects Lots of blood samples from each following single, multiple doses Might randomize according to a single factor, eg fed vs fasting state, evaluate effect on PK parameters Lewis: These can provide Good info on appropriate compartment model Some info on PK parameters and how they vary, but not much Lewis: Can learn a lot more Population studies Study PK in target population of heterogeneous patients undergoing chronic dosing as part of routine clinical care Large number of subjects Sparse, haphazard sampling of each subject Lots of demographic, physiological, behavioral characteristics recorded for each subject, eg weight, age, renal function, race, ethnicity, disease status, smoking, Population PK: Learn about variation of PK parameters in population Associated with subject characteristics (and their interactions) Unexplained by these ( inherent variation? unmeasured factors?) Greenberg Lecture I: PK, PD, and Statistics 31 Greenberg Lecture I: PK, PD, and Statistics 32 4 Population PK/PD and Statistics 4 Population PK/PD and Statistics How to do this? Statistical modeling! Data: Repeated concentration measurements on each of m subjects from the population of interest Y ij Y i u i a i plasma concentration at time t ij, j = 1,, n i (Y i1,, Y ini ) T dosing history for subject (conditions of measurement) subject characteristics (covariates) (Y i, u i, a i) independent across i = 1,, m Perspective: Focus not on population mean concentration, but on population of individual PK parameters in the PK mathematical model Need to embed the PK mathematical model in a statistical model Greenberg Lecture I: PK, PD, and Statistics 33 Statistical model: Sheiner, Rosenberg, and Melmon (1972); Sheiner, Rosenberg, and Marathe (1977) What is now known as a nonlinear mixed effects (hierarchical ) model Stage 1: Intra-subject model Assumption : Observed concentrations equal deterministic mathematical PK model plus deviation due to assay error, realization variance (and model misspecification) The PK model and superposition principle give an expression for concentration at time t under dosing history u f(t, u, β), β = PK parameters (p 1) Eg, β = (k a, Cl, V ) T in the one compartment model Greenberg Lecture I: PK, PD, and Statistics 34 4 Population PK/PD and Statistics 4 Population PK/PD and Statistics Subject i: Subject-specific PK parameters, eg, β i = (k ai, Cl i, V i) T concentration time Y i(t) = f(t, u i, β i ) + e i(t), Y ij = Y i(t ij) Greenberg Lecture I: PK, PD, and Statistics 35 Stage 1: Intra-subject model Result: Y ij = f(t ij, u i, β i ) + e ij Possible intra-subject correlation (usually assumed negligible ) Intra-subject variance about f often small (CV 10-30%), not constant, dominated by assay error Standard : Y ij u i, β i normal or lognormal with E(Y ij u i, β i ) = f(t ij, u i, β i ), var(y ij u i, β i ) = σ 2 f 2 (t ij, u i, β i ) Compactly : Y i = f i (u i, β i ) + e i with E(Y i u i, β i ) = f i (u i, β i ), var(y i u i, β i ) = R i(u i, β i, ξ) Greenberg Lecture I: PK, PD, and Statistics 36 Y i = f i (u i, β i ) + R 1/2 i (u i, β i, ξ)ɛ i }{{} e i
7 4 Population PK/PD and Statistics 4 Population PK/PD and Statistics Stage 2: Inter-subject population model β i = d(a i, θ, b i) (p 1) b i (k 1) random effects H, mean 0 Standard assumption: H is k-variate N k(0, D) Eg Different parameterizations Cl i = θ 1 + θ T 2 a i + b Cl,i, V i = θ 3 + θ T 4 a i + b V,i log Cl i = θ 1 + θ T 2 a i + b Cl,i, log V i = θ 3 + θ T 4 a i + b V,i Often β i = A iθ + B ib i Moderate inter-subject variation in PK parameters (CV 30 70%) Greenberg Lecture I: PK, PD, and Statistics 37 Together: Two-stage hierarchy Intra-subject model (Stage 1 ): Substitute for β i E(Y i u i, a i, b i) = f i {u i, d(a i, θ, b i)}, var(y i u i, a i, b i) = R i{u i, d(a i, θ, b i), ξ} Y i = f i {u i, d(a i, θ, b i)} + R 1/2 i {d(a i, θ, b i), ξ}ɛ i = (Y i u i, a i, b i) has density p y b (y i u i, a i, b i; θ, ξ) Inter-subject population model (Stage 2 ): β i = d(a i, θ, b i), b i H, E(b i) = 0 Subject-matter and statistical principles combined in one framework: Stage 1 : physiological + empirical statistical modeling Stage 2 : empirical statistical modeling Greenberg Lecture I: PK, PD, and Statistics 38 4 Population PK/PD and Statistics 4 Population PK/PD and Statistics Objectives of analysis: Determine d Relationship between PK, covariates Estimate θ Relationship between PK, covariates Estimate H Unexplained variation in population Estimate β i Characterize individuals = individualized dosing Likelihood (conditional on covariates u i, a i): Maximize m m m p y(y i u i, a i) = l i(θ, ξ, H; y i ) = p y b (y i u i, a i, b i; θ, ξ) dh(b i) i=1 i=1 i=1 Complex dosing histories = complex PK model f Intractable integral in general (nonlinear in b i) Greenberg Lecture I: PK, PD, and Statistics 39 Lewis & Co: First-Order method (Beal and Sheiner, 1982) Assume p y b is normal, H is N k(0, D), approximate about b i = 0: Y i = f i {u i, d(a i, θ, b i)} + R 1/2 i {u i, d(a i, θ, b i), ξ}ɛ i f i {u i, d(a i, θ, 0)} + Z i(u i, θ, 0)b i + R 1/2 i {u i, d(a i, θ, 0)}ɛ i Approximate l i by n i-variate normal with E(Y i u i, a i) f i {u i, d(a i, θ, 0)}, var(y i u i, a i) R i{u i, d(a i, θ, 0)} + Z i(u i, θ, 0)DZ T i (u i, θ, 0) Implemented in the FORTRAN program NONMEM (FO method) (University of California, San Francisco) Obvious bias (but worked pretty well in simulations) Generated huge excitement in PK community Greenberg Lecture I: PK, PD, and Statistics 40 4 Population PK/PD and Statistics 4 Population PK/PD and Statistics Meanwhile: Statisticians were just beginning to pay attention Stumpy Giltinan (RIP) Ed Vonesh, PhD Mary Lindstrom, PhD Doug Bates, PhD Greenberg Lecture I: PK, PD, and Statistics 41 Greenberg Lecture I: PK, PD, and Statistics 42
8 4 Population PK/PD and Statistics 4 Population PK/PD and Statistics Main catalyst for statistical research in nonlinear mixed models Better approximations to the integral: Assume H is N k(0, D), p y b normal with R i(u i, β i, ξ) = R i(u i, ξ) Use Laplace s approximation or a Taylor series = l i n i-variate normal with E(Y i u i, a i) f i {u i, d(a i, θ, ˆb i)} Z i{u i, θ, ˆb i}ˆb i var(y i u i, a i) Z i(u i, θ, ˆb i)dz T i (u i, θ, ˆb i) + R i(u i, ξ) Remarks: Lindstrom and Bates (1990), Wolfinger (1993), Vonesh (1996), Implementation : Iterate between updating ˆb i and fitting approximate model Approximation works remarkably well for sparse (small n i) population PK data as long as intra-subject variation is small Variations : R/Splus nlme(), SAS %nlinmix, NONMEM (FOCE method), big advantage PK models built-in! ˆb i = empirical Bayes estimate of b i maximizing p b y (b i u i, a i, y i ) Greenberg Lecture I: PK, PD, and Statistics 43 Greenberg Lecture I: PK, PD, and Statistics 44 4 Population PK/PD and Statistics 4 Population PK/PD and Statistics This motivated lots more Computational work: Why not just do the integral? Deterministic and stochastic numerical integration, eg Variants of quadrature Importance sampling Monte Carlo EM Pinheiro and Bates (1995), Walker (1996) Implementation : SAS proc nlmixed Model refinements: Assumption on H why should b i be normal? Rather than assume a parametric form, estimate the distribution of β i directly nonparametrically (Mallet, 1986, and others) USC*PACK-NPEM (University of Southern California) Or assume H has a nice density and estimate it (Davidian and Gallant, 1993) FORTRAN nlmix (user-unfriendly) Inspect estimates to identify subpopulations, omitted covariates Greenberg Lecture I: PK, PD, and Statistics 45 Greenberg Lecture I: PK, PD, and Statistics 46 4 Population PK/PD and Statistics 4 Population PK/PD and Statistics This was also a natural area for Bayesians Jon Wakefield, PhD Gary Rosner, ScD Peter Müller, PhD Joe Ibrahim, PhD Greenberg Lecture I: PK, PD, and Statistics 47 Greenberg Lecture I: PK, PD, and Statistics 48
9 4 Population PK/PD and Statistics 4 Population PK/PD and Statistics Bayesian view: Add Stage 3 : Hyperprior (β, ξ, D) p β,ξ,d(β, ξ, D) Implementation: To do the intractable integration us MCMC techniques An early showcase for these methods Wakefield (1996), Müller and Rosner (1997) Gelman, Bois, Jiang (1996), Mezzetti, Ibrahim, et al (2003) Parametric (normality) or more flexible models for b i, β i PKBugs, a WinBUGS interface with built-in PK models MCSim, for systems of differential equations (PBPK models) Greenberg Lecture I: PK, PD, and Statistics 49 What about pharmacodynamics? PK is only part of the full story Population PK/PD study : Collect PK/PD data on same subjects PD responses R ij at times t ij (categorical, continuous, surrogate ) Intra-subject PD model : True plasma concentration c ij at t ij R ij = g(c ij, α i) + e ij Joint PK/PD model: Describe c ij by PK model Intra-subject joint PK/PD model Y ij = f(t ij, u i, β i ) + e ij, Emaxi E0i eg g(c, α i) = E 0i EC 50/c R ij = g{f(t ij, u i, β i ), α i} + e ij β i = d(a i, θ, b i), α i = d (a i, γ, b i ), (b T i, b T i ) H Often : Incorporate a lag between PK and PD in the joint model Greenberg Lecture I: PK, PD, and Statistics 50 4 Population PK/PD and Statistics 4 Population PK/PD and Statistics Extensions and by-products: Individual estimation : Use posterior modes to estimate β i (and α i) Bayesian dosage adjustment : Use these for current or future subjects given a few observations = Individual dosing regimen Inter-occasion variation parameters may vary within the same individual, implications for dosing Non/semiparametric population models Censored concentrations/response Missing/mismeasured covariates Etc Summary: By the late-1990s Lots of statistical research Nonlinear mixed effects models became standard tools Exploited, enhanced by PK/PD community = specialized software implementing one or more of these methods (and built-in catalogs of PK/PD models) NONMEM (UCSF, now GloboMax) ADAPT II (University of Southern California) WinNonMix (Pharsight Corporation) Etc Greenberg Lecture I: PK, PD, and Statistics 51 Greenberg Lecture I: PK, PD, and Statistics 52 5 Example 5 Example World-famous example: Population PK of phenobarbital Dosing history and concentrations for one subject: m = 59 pre-term infants treated for seizures n i = 1 to 6 concentration measurements per subject, total of 155 measurements Birth weight w i and 5-minute Apgar score δ i = I[Apgar < 5] IV multiple doses; one-compartment model f(t ij, u i, β i ) = { } D id exp Cli (t t id) V i V i d:tid<t Objectives: Characterize PK and its variation (typical Cl i, V i? do covariates matter? extent of biological variation?) Phenobarbital conc (mcg/ml) Time (hours) Greenberg Lecture I: PK, PD, and Statistics 53 Greenberg Lecture I: PK, PD, and Statistics 54
10 5 Example 5 Example Inter-subject models: β i = (Cl i, V i) T Without covariates log Cl i = θ 1 + b 1i, log V i = θ 2 + b 2i Final model with covariates log Cl i = θ 1 + θ 3w i + b 1i, log V i = θ 2 + θ 4w i + θ 5δ i + b 2i Clearance random effect Clearance random effect Birth weight Apgar<5 Apgar>=5 Apgar score Volume random effect Volume random effect Birth weight Apgar<5 Apgar>=5 Apgar score Greenberg Lecture I: PK, PD, and Statistics 55 Greenberg Lecture I: PK, PD, and Statistics 56 5 Example 5 Example Clearance random effect Birth weight Volume random effect Birth weight Density estimates: h Volume -04 (a) Clearance h Volume -06 (b) Clearance Clearance random effect Apgar<5 Apgar score Apgar>=5 Volume random effect Apgar<5 Apgar score Apgar>=5 Volume (c) Clearance Volume (d) Clearance Greenberg Lecture I: PK, PD, and Statistics 57 Greenberg Lecture I: PK, PD, and Statistics 58 6 PK/PD Today 6 PK/PD Today Population PK/PD analysis: Is an important component of the drug development process Recognized benefit: Identifying differences in drug safety and efficacy among population subgroups that can be addressed by dose modification particularly when intended population is quite heterogeneous and typical therapeutic window is narrow Is an important component of the regulatory process Guidance for Industry Population Pharmacokinetics US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) February 1999 CP 1 Greenberg Lecture I: PK, PD, and Statistics 59 Greenberg Lecture I: PK, PD, and Statistics 60
11 6 PK/PD Today 6 PK/PD Today Current interest: Clinical Pharmacology Subcommittee of the FDA Advisory Committee for Pharmaceutical Science A population PK/PD guidance Incorporation of genetic information Special design/model considerations for pediatric populations Greenberg Lecture I: PK, PD, and Statistics 61 Clinical trial simulation: Use PK, PD info to target, design trials Pharsight Corporation (and others) Ingredients: Based on prior PK/PD investigation Covariate distribution model : A model for the target population PK model : Hierarchical model incorporating covariates impacting PK = concentrations PD model : Hierarchical model incorporating concentrations, covariates impacting PD = responses (also placebo model) Hazard model : Relating responses to a clinical endpoint Simulation: Generate samples of patients under different designs (numbers, inclusion criteria, dose regimens, etc) End-of-Phase-2a Meetings Greenberg Lecture I: PK, PD, and Statistics 62 7 Concluding Remarks 7 Concluding Remarks Population PK/PD analysis: A statistical success story Statistical modeling is central to the subject-matter science A model for other biomedical research Currently: Great interest in combining mathematical and statistical modeling to address other questions, eg, treatment of HIV infection Potent antiretroviral drugs cannot be taken continually What is the best strategy for treatment? A promising tool: Within-subject HIV dynamical systems models Describe the interplay between virus and immune system over time, incorporates effects of treatment Can these models be used to develop dynamic treatment regimes for HIV infection? Tomorrow afternoon! Greenberg Lecture I: PK, PD, and Statistics 63 Greenberg Lecture I: PK, PD, and Statistics 64 7 Concluding Remarks 7 Concluding Remarks 10 5 Model Fits to the Clinical Data 10 4 data model fit censored data virus copies/ml time (days) Greenberg Lecture I: PK, PD, and Statistics 65 Greenberg Lecture I: PK, PD, and Statistics 66
12 7 Concluding Remarks Dedication Where to get a copy of these slides: davidian This talk is dedicated to the memory of Where to find a great intro course on PK on the web: Thanks to David Bourne at University of Oklahoma for some of the pictures in this talk! Some books about PK/PD: Rowland, M and Tozer, TN, Clinical Pharmaockinetics: Concepts and Applications (nth edition) Gibaldi, M and Perrier, D, Pharmacokinetics (2nd edition) Journal with lots of statistical content: Journal of Pharmacokinetics and Pharmacodynamics (formerly Journal of Pharmacokinetics and Biopharmaceutics) Greenberg Lecture I: PK, PD, and Statistics 67 Lewis B Sheiner, MD Greenberg Lecture I: PK, PD, and Statistics 68
Mathematical-Statistical Modeling to Inform the Design of HIV Treatment Strategies and Clinical Trials
Mathematical-Statistical Modeling to Inform the Design of HIV Treatment Strategies and Clinical Trials 2007 FDA/Industry Statistics Workshop Marie Davidian Department of Statistics North Carolina State
More informationMathematical-Statistical Modeling to Inform the Design of HIV Treatment Strategies and Clinical Trials
Mathematical-Statistical Modeling to Inform the Design of HIV Treatment Strategies and Clinical Trials Marie Davidian and H.T. Banks North Carolina State University Eric S. Rosenberg Massachusetts General
More informationPKPD modelling to optimize dose-escalation trials in Oncology
PKPD modelling to optimize dose-escalation trials in Oncology Marina Savelieva Design of Experiments in Healthcare, Issac Newton Institute for Mathematical Sciences Aug 19th, 2011 Outline Motivation Phase
More informationPopulation Pharmacokinetics and Pharmacodynamics as a Tool in Drug Development. Leon Aarons Manchester Pharmacy School University of Manchester
Population Pharmacokinetics and Pharmacodynamics as a Tool in Drug Development Leon Aarons Manchester Pharmacy School University of Manchester Pharmacokinetics and Pharmacodynamics Clinical Pharmacokinetics
More informationExposure-response in the presence of confounding
Exposure-response in the presence of confounding Jonathan L. French, ScD Metrum Research Group LLC May 3, 2016 c 2016 Metrum Research Group LLC TICTS, Durham, NC, 2016 May 3, 2016 1 / 24 Outline 1 Introduction
More informationPOPULATION PHARMACOKINETICS RAYMOND MILLER, D.Sc. Daiichi Sankyo Pharma Development
POPULATION PHARMACOKINETICS RAYMOND MILLER, D.Sc. Daiichi Sankyo Pharma Development Definition Population Pharmacokinetics Advantages/Disadvantages Objectives of Population Analyses Impact in Drug Development
More informationPharmacometric Modelling to Support Extrapolation in Regulatory Submissions
Pharmacometric Modelling to Support Extrapolation in Regulatory Submissions Kristin Karlsson, PhD Pharmacometric/Pharmacokinetic assessor Medical Products Agency, Uppsala,Sweden PSI One Day Extrapolation
More informationPOPULATION PHARMACOKINETICS. Population Pharmacokinetics. Definition 11/8/2012. Raymond Miller, D.Sc. Daiichi Sankyo Pharma Development.
/8/202 POPULATION PHARMACOKINETICS Raymond Miller, D.Sc. Daiichi Sankyo Pharma Development Population Pharmacokinetics Definition Advantages/Disadvantages Objectives of Population Analyses Impact in Drug
More informationModeling & Simulation to support evaluation of Safety and Efficacy of Drugs in Older Patients
Modeling & Simulation to support evaluation of Safety and Efficacy of Drugs in Older Patients Eva Bredberg, Director Global Clinical Pharmacology, AstraZeneca On behalf of EFPIA EMA Geriatrics Workshop
More informationBiomath M263 Clinical Pharmacology
Training Program in Translational Science Biomath M263 Clinical Pharmacology Spring 2013 www.ctsi.ucla.edu/education/training/webcasts Wednesdays 3 PM room 17-187 CHS 4/3/2013 Pharmacokinetics and Pharmacodynamics
More informationBasic Concepts of TDM
TDM Lecture 1 5 th stage What is TDM? Basic Concepts of TDM Therapeutic drug monitoring (TDM) is a branch of clinical pharmacology that specializes in the measurement of medication concentrations in blood.
More informationPOPULATION PHARMACOKINETICS
POPULATION PHARMACOKINETICS Raymond Miller, D.Sc. Daiichi Sankyo Pharma Development 1 Population Pharmacokinetics Definition Advantages/Disadvantages Objectives of Population Analyses Impact in Drug Development
More informationSYNOPSIS. The study results and synopsis are supplied for informational purposes only.
SYNOPSIS INN : LEFLUNOMIDE Study number : HMR486/1037 et HMR486/3503 Study title : Population pharmacokinetics of A77 1726 (M1) after oral administration of leflunomide in pediatric subjects with polyarticular
More informationBASIC PHARMACOKINETICS
BASIC PHARMACOKINETICS MOHSEN A. HEDAYA CRC Press Taylor & Francis Croup Boca Raton London New York CRC Press is an imprint of the Taylor & Francis Group, an informa business Table of Contents Chapter
More informationCase Study in Placebo Modeling and Its Effect on Drug Development
Case Study in Placebo Modeling and Its Effect on Drug Development Modeling and Simulation Strategy for Phase 3 Dose Selection of Dasotraline in Patients With Attention-Deficit/Hyperactivity Disorder Julie
More informationSub Population: The elderly
Sub Population: The elderly How can Modelling and Simulation inform understanding of safety and efficacy? Amy S. Y. Cheung, Senior Clinical Pharmacometrician Early Clinical Development, AstraZeneca On
More informationCLINICAL TRIAL SIMULATION & ANALYSIS
1 CLINICAL TRIAL SIMULATION & ANALYSIS Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland, New Zealand NHG Holford, 217, all rights reserved. 2 SIMULATION Visualise the expected
More informationBayesian and Frequentist Approaches
Bayesian and Frequentist Approaches G. Jogesh Babu Penn State University http://sites.stat.psu.edu/ babu http://astrostatistics.psu.edu All models are wrong But some are useful George E. P. Box (son-in-law
More informationOutline. What is a VPC? Model Evaluation. What is a Visual Predictive Check? What choices are there in presentation? What can it help to show?
1 Model Evaluation Visual Predictive Checks www.page-meeting.org/?abstract=1434 PAGE 2008 Marseille Nick Holford University of Auckland Mats Karlsson University of Uppsala 2 Outline What is a Visual Predictive
More informationHierarchical Bayesian Methods for Estimation of Parameters in a Longitudinal HIV Dynamic System
Hierarchical Bayesian Methods for Estimation of Parameters in a Longitudinal HIV Dynamic System Yangxin Huang, Dacheng Liu and Hulin Wu Department of Biostatistics & Computational Biology University of
More informationApplied Biopharmaceutics & Pharmacokinetics Sixth Edition
Applied Biopharmaceutics & Pharmacokinetics Sixth Edition Hill Leon Shargel, PHD, RPh Applied Biopharmaceutics, LLC Raleigh, North Carolina Affiliate Associate Professor, School of Pharmacy Virginia Commonwealth
More informationRisk and Benefit Assessments for Optimal Dose Selection Based on Exposure Response
Risk and Benefit Assessments for Optimal Dose Selection Based on Exposure Response 2003 FDA/Industry Statistics Workshop Peter I. Lee, PhD Associate Director, Pharmacometrics OCPB, CDER, FDA Disclaimers
More informationPractical Bayesian Design and Analysis for Drug and Device Clinical Trials
Practical Bayesian Design and Analysis for Drug and Device Clinical Trials p. 1/2 Practical Bayesian Design and Analysis for Drug and Device Clinical Trials Brian P. Hobbs Plan B Advisor: Bradley P. Carlin
More informationBayesian Methods in Regulatory Science
Bayesian Methods in Regulatory Science Gary L. Rosner, Sc.D. Regulatory-Industry Statistics Workshop Washington, D.C. 13 September 2018 What is Regulatory Science? US FDA Regulatory Science is the science
More informationBIOPHARMACEUTICS and CLINICAL PHARMACY
11 years papers covered BIOPHARMACEUTICS and CLINICAL PHARMACY IV B.Pharm II Semester, Andhra University Topics: Absorption Distribution Protein binding Metabolism Excretion Bioavailability Drug Interactions
More informationTitle: Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations
1 SUPPLEMENTARY MATERIALS 2 3 4 5 6 7 8 Title: Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two Phase 2 clinical trials Authors: Radojka M. Savic,
More informationST440/550: Applied Bayesian Statistics. (10) Frequentist Properties of Bayesian Methods
(10) Frequentist Properties of Bayesian Methods Calibrated Bayes So far we have discussed Bayesian methods as being separate from the frequentist approach However, in many cases methods with frequentist
More information1. If the MTC is 100 ng/ml and the MEC is 0.12 ng/ml, which of the following dosing regimen(s) are in the therapeutic window?
Page 1 PHAR 750: Biopharmaceutics/Pharmacokinetics October 23, 2009 - Form 1 Name: Total 100 points Please choose the BEST answer of those provided. For numerical answers, choose none of the above if your
More informationScientific And Regulatory Background For The Revised Bioequivalence Requirements For NTI, Steep Exposure-Response, And Drugs With Complex PK Profiles
Scientific And Regulatory Background For The Revised Bioequivalence Requirements For NTI, Steep Exposure-Response, And Drugs With Complex PK Profiles Liang Zhao, Ph.D. Director, Division of Quantitative
More informationEXTRAPOLATION CHALLENGES IN PEDIATRIC PAH
EXTRAPOLATION CHALLENGES IN PEDIATRIC PAH Possible solutions for a feasible, global study M. Bacchi, A. Morganti, P. Cornelisse, J. Bolognese, C. Lesage, A. Kümmel, P. Nilsson Copyright 2016 Actelion Pharmaceuticals
More informationBasic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook with Computer Simulations
Basic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook with Computer Simulations Rosenbaum, Sara E. ISBN-13: 9780470569061 Table of Contents 1 Introduction to Pharmacokinetics and Pharmacodynamics.
More informationModeling and Simulation to Support Development and Approval of Complex Products
Modeling and Simulation to Support Development and Approval of Complex Products Mathangi Gopalakrishnan, MS, PhD Research Assistant Professor Center for Translational Medicine, School of Pharmacy, UMB
More informationIndividualized Treatment Effects Using a Non-parametric Bayesian Approach
Individualized Treatment Effects Using a Non-parametric Bayesian Approach Ravi Varadhan Nicholas C. Henderson Division of Biostatistics & Bioinformatics Department of Oncology Johns Hopkins University
More informationSummary Report for HIV Random Clinical Trial Conducted in
Summary Report for HIV Random Clinical Trial Conducted in 9-2014 H.T. Banks and Shuhua Hu Center for Research in Scientific Computation North Carolina State University Raleigh, NC 27695-8212 USA Eric Rosenberg
More informationIntroduction to Pharmacokinetics (PK) Anson K. Abraham, Ph.D. Associate Principal Scientist, PPDM- QP2 Merck & Co. Inc., West Point, PA 5- June- 2017
Introduction to Pharmacokinetics (PK) Anson K. Abraham, Ph.D. Associate Principal Scientist, PPDM- QP2 Merck & Co. Inc., West Point, PA 5- June- 2017 1 Outline Definition & Relevance of Pharmacokinetics
More informationClinical Trials A Practical Guide to Design, Analysis, and Reporting
Clinical Trials A Practical Guide to Design, Analysis, and Reporting Duolao Wang, PhD Ameet Bakhai, MBBS, MRCP Statistician Cardiologist Clinical Trials A Practical Guide to Design, Analysis, and Reporting
More informationQuantifying and Mitigating the Effect of Preferential Sampling on Phylodynamic Inference
Quantifying and Mitigating the Effect of Preferential Sampling on Phylodynamic Inference Michael D. Karcher Department of Statistics University of Washington, Seattle April 2015 joint work (and slide construction)
More informationAdaptive and Innovative Study Designs to Accelerate Drug Development from First-In-Human to First-In-Patient
Adaptive and Innovative Study Designs to Accelerate Drug Development from First-In-Human to First-In-Patient Michelle L. Combs, PhD Vice President, Clinical Pharmacology Sciences New Drug And Biologics
More informationA Mechanism-Based PK/PD Model Predicts the Time-Course of Hematological responses for Epoetin beta
A Mechanism-Based PK/PD Model Predicts the Time-Course of Hematological responses for Epoetin beta N. Hayashi, K. P. Zuideveld, P. Jordan & R. Gieschke Modeling & Simulation Group & Biometrics, F. Hoffmann-La
More informationMultiple IV Bolus Dose Administration
PHARMACOKINETICS Multiple IV Bolus Dose Administration ١ Multiple IV Bolus Dose Administration Objectives: 1) To understand drug accumulation after repeated dose administration 2) To recognize and use
More informationPKPD-Modelling of QT Prolongation Following Deliberate Self-Poisonings with Citalopram
PKPD-Modelling of QT Prolongation Following Deliberate Self-Poisonings with Citalopram Lena Friberg 1, Geoffrey Isbister 2, Peter Hackett 3 and Stephen Duffull 1 1 School of Pharmacy, University of Queensland,
More informationFDA Use of Big Data in Modeling and Simulations
FDA Use of Big Data in Modeling and Simulations Jeffry Florian, Ph.D., Division of Pharmacometrics, CDER/OTS/OCP/DPM DISCLAIMER: The views expressed in this presentation are that of the author and do not
More informationNontraditional PharmD Program PRDO 7700 Pharmacokinetics Review Self-Assessment
Nontraditional PharmD Program PRDO 7700 Pharmacokinetics Review Self-Assessment Please consider the following questions. If you do not feel confident about the material being covered, then it is recommended
More informationDrug-Disease Modeling Applied to Drug Development and Regulatory Decision Making in the Type 2 Diabetes Mellitus Arena
Drug-Disease Modeling Applied to Drug Development and Regulatory Decision Making in the Type 2 Diabetes Mellitus Arena Tokyo, Japan, December 8, 2015 Stephan Schmidt, Ph.D. Assistant Professor Center for
More informationDRAFT GUIDANCE DOCUMENT Comparative Bioavailability Standards: Formulations Used for Systemic Effects
1 2 3 DRAFT GUIDANCE DOCUMENT Comparative Bioavailability Standards: Formulations Used for Systemic Effects 4 This guidance document is being distributed for comment purposes only. 5 6 Published by authority
More informationLecture Outline. Biost 590: Statistical Consulting. Stages of Scientific Studies. Scientific Method
Biost 590: Statistical Consulting Statistical Classification of Scientific Studies; Approach to Consulting Lecture Outline Statistical Classification of Scientific Studies Statistical Tasks Approach to
More informationYangxin Huang a & Hulin Wu b a Department of Epidemiology & Biostatistics, College of Public
This article was downloaded by: [University of Prince Edward Island] On: 15 April 2013, At: 05:06 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered
More informationModel-based quantification of the relationship between age and anti-migraine therapy
6 Model-based quantification of the relationship between age and anti-migraine therapy HJ Maas, M Danhof, OE Della Pasqua Submitted to BMC. Clin. Pharmacol. Migraine is a neurological disease that affects
More informationBayesian Nonparametric Methods for Precision Medicine
Bayesian Nonparametric Methods for Precision Medicine Brian Reich, NC State Collaborators: Qian Guan (NCSU), Eric Laber (NCSU) and Dipankar Bandyopadhyay (VCU) University of Illinois at Urbana-Champaign
More informationDr. Nele Plock. Dr. N. Plock, March 11, 2008, American Conference on Pharmacometrics
Parallel PKPD modeling of an endogenous agonist (A) and exogenous antagonist (B) based on research PKPD data to predict an effective first-in-man dose of B A combination of physiologically based PK and
More informationPharmacokinetic and absolute bioavailability studies in early clinical development using microdose and microtracer approaches.
Pharmacokinetic and absolute bioavailability studies in early clinical development using microdose and microtracer approaches. Lloyd Stevens PhD Senior Research Fellow Pharmaceutical Profiles Nottingham,
More informationPK-PD modelling to support go/no go decisions for a novel gp120 inhibitor
PK-PD modelling to support go/no go decisions for a novel gp120 inhibitor Phylinda LS Chan Pharmacometrics, Pfizer, UK EMA-EFPIA Modelling and Simulation Workshop BOS1 Pharmacometrics Global Clinical Pharmacology
More informationSection 5.2: Pharmacokinetic properties
Section 5.2: Pharmacokinetic properties SmPC training presentation Note: for full information refer to the European Commission s Guideline on summary of product characteristics (SmPC) SmPC Advisory Group
More informationOne-Compartment Open Model: Intravenous Bolus Administration:
One-Compartment Open Model: Intravenous Bolus Administration: Introduction The most common and most desirable route of drug administration is orally by mouth using tablets, capsules, or oral solutions.
More informationStrategies for Developing and Validating PBPK Models for Extrapolation to Unstudied Population
Strategies for Developing and Validating PBPK Models for Extrapolation to Unstudied Population Nina Isoherranen Department of Pharmaceutics University of Washington Processes driving drug disposition are
More informationBayesian graphical models for combining multiple data sources, with applications in environmental epidemiology
Bayesian graphical models for combining multiple data sources, with applications in environmental epidemiology Sylvia Richardson 1 sylvia.richardson@imperial.co.uk Joint work with: Alexina Mason 1, Lawrence
More informationPharmacodynamics & Pharmacokinetics 1
PCTH 325 Pharmacodynamics & Pharmacokinetics 1 Dr. Shabbits jennifer.shabbits@ubc.ca September 9, 2014 Learning objectives 1. Describe the categories of intended drug action 2. Compare and contrast agonists
More informationDOSE SELECTION FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS *)
DOSE SELECTION FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS *) Guideline Title Dose Selection for Carcinogenicity Studies of Pharmaceuticals *) Legislative basis Directive 75/318/EEC as amended Date
More informationA Brief Introduction to Bayesian Statistics
A Brief Introduction to Statistics David Kaplan Department of Educational Psychology Methods for Social Policy Research and, Washington, DC 2017 1 / 37 The Reverend Thomas Bayes, 1701 1761 2 / 37 Pierre-Simon
More informationAbsolute bioavailability and pharmacokinetic studies in early clinical development using microdose and microtracer approaches.
Absolute bioavailability and pharmacokinetic studies in early clinical development using microdose and microtracer approaches. Dr Lloyd Stevens Senior Research Fellow Pharmaceutical Profiles Nottingham,
More informationCombining Risks from Several Tumors Using Markov Chain Monte Carlo
University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln U.S. Environmental Protection Agency Papers U.S. Environmental Protection Agency 2009 Combining Risks from Several Tumors
More informationAccommodating informative dropout and death: a joint modelling approach for longitudinal and semicompeting risks data
Appl. Statist. (2018) 67, Part 1, pp. 145 163 Accommodating informative dropout and death: a joint modelling approach for longitudinal and semicompeting risks data Qiuju Li and Li Su Medical Research Council
More informationThe Chemostat: Stability at Steady States. Chapter 5: Linear & Non-Linear Interaction Models. So, in dimensional form, α 1 > 1 corresponds to
Introduction & Simple Models Logistic Growth Models The Chemostat: Stability at Steady States 1 So, in dimensional form, α 1 > 1 corresponds to K max < V F. As K max is max bacterial repro rate with unlimited
More informationLecture 1: Introduction to Personalized Medicine. Donglin Zeng, Department of Biostatistics, University of North Carolina
Lecture 1: Introduction to Personalized Medicine Personalized Medicine A Quick View Personalized Medicine is a general medical paradigm referring to systematic use of individual patient information to
More informationThe general Concepts of Pharmacokinetics
The general Concepts of Pharmacokinetics What is this jargon? Is it useful? C max, clearance, Vd, half-life, AUC, bioavailability, protein binding F. Van Bambeke, E. Ampe, P.M. Tulkens (Université catholique
More informationCounty-Level Small Area Estimation using the National Health Interview Survey (NHIS) and the Behavioral Risk Factor Surveillance System (BRFSS)
County-Level Small Area Estimation using the National Health Interview Survey (NHIS) and the Behavioral Risk Factor Surveillance System (BRFSS) Van L. Parsons, Nathaniel Schenker Office of Research and
More informationUsing Statistical Principles to Implement FDA Guidance on Cardiovascular Risk Assessment for Diabetes Drugs
Using Statistical Principles to Implement FDA Guidance on Cardiovascular Risk Assessment for Diabetes Drugs David Manner, Brenda Crowe and Linda Shurzinske BASS XVI November 9-13, 2009 Acknowledgements
More informationICH Topic S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals. Step 5
European Medicines Agency October 2008 EMEA/CHMP/ICH/383/1995 ICH Topic S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON DOSE SELECTION FOR CARCINOGENICITY
More informationViera Lukacova Director, Simulation Sciences
Use of In Silico Mechanistic Models to Support Interspecies Extrapolation of Oral Bioavailability and Formulation Optimization: Model Example Using GastroPlus Viera Lukacova Director, Simulation Sciences
More informationMathematical Framework for Health Risk Assessment
Mathematical Framework for Health Risk Assessment Health Risk Assessment Does a substance pose a health hazard and, if so how is it characterized? A multi-step process Risk Characterization MSOffice1 Hazard
More informationGap identification as a critical step to enable integrated clinical trial simulation platforms
Gap identification as a critical step to enable integrated clinical trial simulation platforms Application to TB Eline van Maanen Joost de Jongh Peter Vis September 26, 2013 LEIDEN EXPERTS ON ADVANCED
More informationPharmacokinetics One- compartment Open Model Lec:2
22 Pharmacokinetics One- compartment Open Model Lec:2 Ali Y Ali BSc Pharmacy MSc Industrial Pharmaceutical Sciences Dept. of Pharmaceutics School of Pharmacy University of Sulaimani 1 Outline Introduction
More informationAdjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes
Adjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes Brian Hardy, PharmD, FCSHP, FCCP Coordinator Education and Clinical Programs Department of Pharmacy Sunnybrook
More informationMedian (Min Max) CVC 100 mg + EFV placebo + TDF/FTC (N=8) CVC 200 mg + EFV placebo + TDF/FTC (N=10) LLOQ=5.00 ng/ml Time (h)
600 Pharmacokinetics (Pk) of cenicriviroc (cvc) following 100 or 200 mg once-daily Dosing with open-label tenofovir / emtricitabine (tdf/ftc) in hiv-1 infected subjects enrolled in a Phase 2b study David
More informationBasic pharmacokinetics. Frédérique Servin APHP hôpital Bichat Paris, FRANCE
Basic pharmacokinetics Frédérique Servin APHP hôpital Bichat Paris, FRANCE DOSE CONCENTRATION EFFECT Pharmacokinetics What the body does to the drug Pharmacodynamics What the drug does to the body Transfer
More informationReflection paper on the use of extrapolation in the development of medicines for paediatrics
7 October 2018 EMA/189724/2018 Reflection paper on the use of extrapolation in the development of medicines for paediatrics Final Draft agreed by Biostatistics Working Party, Modelling and Simulation September
More informationTDM of Aminoglycoside Antibiotics
TDM Lecture 3 5 th Stage TDM of Aminoglycoside Antibiotics The aminoglycoside antibiotics are widely used for the treatment of gram-negative infections, often in combination with a β-lactam antibiotic
More informationPharmacokinetics Overview
Pharmacokinetics Overview Disclaimer: This handout and the associated lectures are intended as a very superficial overview of pharmacokinetics. Summary of Important Terms and Concepts - Absorption, peak
More informationPharmacokinetics and bioavailability derived from various body fluids. Saliva samples instead of plasma samples
Pharmacokinetics and bioavailability derived from various body fluids Saliva samples instead of plasma samples Willi Cawello, Schwarz BioSciences, Monheim am Rhein 1 Overview Introduction Sampling tissues/fluids
More informationModelling heterogeneity variances in multiple treatment comparison meta-analysis Are informative priors the better solution?
Thorlund et al. BMC Medical Research Methodology 2013, 13:2 RESEARCH ARTICLE Open Access Modelling heterogeneity variances in multiple treatment comparison meta-analysis Are informative priors the better
More informationTime to Lowest BIS after an Intravenous Bolus and an Adaptation of the Time-topeak-effect
Adjustment of k e0 to Reflect True Time Course of Drug Effect by Using Observed Time to Lowest BIS after an Intravenous Bolus and an Adaptation of the Time-topeak-effect Algorithm Reported by Shafer and
More informationNOTE FOR GUIDANCE ON TOXICOKINETICS: THE ASSESSMENT OF SYSTEMIC EXPOSURE IN TOXICITY STUDIES S3A
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE NOTE FOR GUIDANCE ON TOXICOKINETICS: THE ASSESSMENT
More informationClinical Study Report AI Final 28 Feb Volume: Page:
Study Design, Continued Electrocardiogram (ECG) and vital sign assessments were done at select times during the study. Blood and urine samples for clinical laboratory evaluations were collected at specified
More informationCurrent Challenges and Opportunities in Demonstrating Bioequivalence
Current Challenges and Opportunities in Demonstrating Bioequivalence Gur Jai Pal Singh, Ph.D. Watson Laboratories, Inc. Corona, California, USA Demonstrating Bioequivalence of Locally Acting Orally Inhaled
More informationPK/PD analysis in assessment of abuse deterrence
PK/PD analysis in assessment of abuse deterrence Megan J. Shram, PhD Director and Principal, Altreos Research Partners Inc. Adjunct Professor and Lecturer, Department of Pharmacology, University of Toronto
More informationApplication of Bayesian Extrapolation in Pediatric Drug Development Program
Application of Bayesian Extrapolation in Pediatric Drug Development Program May Mo, Amy Xia Amgen Regulatory-Industry Statistics Workshop Sep 13, 2018 Washington, DC Disclaimer: The views expressed herein
More informationUnderstand the physiological determinants of extent and rate of absorption
Absorption and Half-Life Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland, New Zealand Objectives Understand the physiological determinants of extent and rate of absorption
More informationGuidance for Industry
Reprinted from FDA s website by Guidance for Industry E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs Questions and Answers (R1) U.S. Department
More informationDecision Making in Confirmatory Multipopulation Tailoring Trials
Biopharmaceutical Applied Statistics Symposium (BASS) XX 6-Nov-2013, Orlando, FL Decision Making in Confirmatory Multipopulation Tailoring Trials Brian A. Millen, Ph.D. Acknowledgments Alex Dmitrienko
More informationA Comparison of Methods for Determining HIV Viral Set Point
STATISTICS IN MEDICINE Statist. Med. 2006; 00:1 6 [Version: 2002/09/18 v1.11] A Comparison of Methods for Determining HIV Viral Set Point Y. Mei 1, L. Wang 2, S. E. Holte 2 1 School of Industrial and Systems
More informationBasic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy
Basic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy I. General principles Applied pharmacokinetics - the process of using drug concentrations, pharmaco-kinetic
More informationMODEL-BASED DOSE INDIVIDUALIZATION APPROACHES USING BIOMARKERS
MODEL-BASED DOSE INDIVIDUALIZATION APPROACHES USING BIOMARKERS CATHERINE M SHERWIN PAGE 27 th Meeting, Montreux, Switzerland 30 th May 2018 Division of Clinical Pharmacology, Pediatrics, School of Medicine
More informationpharmacy, we need to see how clinical pharmacokinetics fits into the pharmaceutical care process.
Therapeutic drug monitoring (TDM) Is a tool that can guide the clinician to provide effective and safe drug therapy in the individual patient. Monitoring can be used to confirm a plasma drug concentration
More informationPHA 4120 Second Exam Key Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 4120 Second Exam Key Fall 1997 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question Points 1. /10 ponts 2. /20 points 3. /10 points 4. /10 points
More informationPHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Final Exam Fall 2012 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Please transfer the answers onto the bubble sheet. The question number refers
More informationLD = (Vd x Cp)/F (Vd x Cp)/F MD = (Css x CL x T)/F DR = (Css x (Vm-DR))/Km Css = (F x D)/(CL x T) (Km x DR)/(Vm DR)
PHARMKIN WORKSHOP A PHARMACOKINETICS TEACHING SIMULATION Joseph K. Ritter, Ph.D. Associate Professor, Pharmacology and Toxicology MSB 536, 828-1022, jritter@mail2.vcu.edu Tompkins-McCaw Libray Room 2-006
More informationCase Studies in Bayesian Augmented Control Design. Nathan Enas Ji Lin Eli Lilly and Company
Case Studies in Bayesian Augmented Control Design Nathan Enas Ji Lin Eli Lilly and Company Outline Drivers for innovation in Phase II designs Case Study #1 Pancreatic cancer Study design Analysis Learning
More informationPhysiologically based pharmacokinetic modeling in risk assessment
nr 2001:6 Physiologically based pharmacokinetic modeling in risk assessment Development of Bayesian population methods Fredrik Jonsson Division of Pharmacokinetics and Drug Therapy, Uppsala University
More informationAdvanced IPD meta-analysis methods for observational studies
Advanced IPD meta-analysis methods for observational studies Simon Thompson University of Cambridge, UK Part 4 IBC Victoria, July 2016 1 Outline of talk Usual measures of association (e.g. hazard ratios)
More information